<DOC>
	<DOCNO>NCT01127360</DOCNO>
	<brief_summary>Age-related macular degeneration ( AMD ) common cause blindness individual 50 year age . Bevacizumab ranibizumab two agent developed American pharmaceutical corporation Genentech , inhibit blood vessel growth factor . These drug , inject intraocularly , reduce pathological growth blood vessel macular area eye . Bevacizumab ( Avastin ) antibody develop intravenous treatment metastasize colon cancer . Ranibizumab ( Lucentis ) antibody fragment develop similar antibody . It introduce 2006 effective treatment wet AMD . Treatment cost , however , 50 time higher compare use bevacizumab . Avastin show similar effect ranibizumab , use off-label many country , Lucentis receive approval . There thus recognize need large randomized study garner proper scientific proof Avastin 's effectiveness regard exudative AMD . LUCAS randomize multicenter study , perform Norway , compare ranibizumab bevacizumab use AMD . The goal study demonstrate two agent equivalent regard efficacy safety . A total 441 patient objective evidence wet AMD randomize double-blind treatment ranibizumab bevacizumab course 2 year . The treatment interval determine `` Treat Extend '' protocol .</brief_summary>
	<brief_title>LUCAS ( Lucentis Compared Avastin Study )</brief_title>
	<detailed_description>LUCAS ( LUcentis Compared Avastin Study ) A randomize , double-blind , prospective multicenter study compare effect intravitreal injection bevacizumab ( Avastin ) ranibizumab ( Lucentis ) give patient exudative ( wet ) age-related macular degeneration Norway . Version : 4 , Protocol : 166-09 , EudraCT : 2008-004225-41 Purpose : LUCAS prospective , randomize , multicenter study compare effect intravitreal injection bevacizumab ( Avastin ) ranibizumab ( Lucentis ) give patient exudative ( wet ) AMD Norway . The study include 420 patient recruit start March 2009 . The study continue 2 year complete enrollment . Design : LUCAS multicenter , randomize , double-blind study , 1:1 parallel group treat either bevacizumab ( Avastin ) 0.05 ml ( 25 mg/ml ) ranibizumab ( Lucentis ) 0,05 ml ( 10 mg/ml ) . The drug inject intravitreally accord `` inject extend '' principle ( 5 ) . Randomization stratify center perform minimization accord prognostic factor . Treatment Regimen : Bevacizumab ( Avastin ) give intravitreal injection 0.05ml ( 25 mg/ml ) vial contain 4 ml . Ranibizumab ( Lucentis ) give intravitreal injection 0.05 ml ( 10 mg/ml ) vial contain 0.23 ml . Follow-up treatment follow principle call `` inject extend . '' This connote follow : initial follow-up injection 4 week interval macula dry . When dry , follow-up injection increase 2 week time . If patient recurrence wet AMD , interval reduce 2 week time macula dry . The short interval 4 week . When extend , treatment interval shall long interval original recurrence , could confer risk new activity . Therefore follow-up injection occur `` ideal '' interval hereby define 2 week less original recurrence . With method , patient receives injection follow-up , presume complication occur . The maximum interval limit 12 week . Treatment continue 2 year . After study complete , patient offer continued treatment , accordance ophthalmology department 's routine , If response treatment 3 injection 4 week interval , patient shall remove study offer alternative treatment , combination treatment photodynamic therapy ( PDT ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Men woman . 2 . Age ≥50 year . 3 . Wet AMD study eye , define : Not previously treat active choroidal neovascular membrane ( CNV ) , include retinal angiomatous proliferation ( RAP ) , edema involve fovea demonstrate optical coherence tomography ( OCT ) fluorescein angiography ( FA ) . FA shall older 7 day randomization . Best correct visual acuity ( BCVA ) study eye 20/25 20/320 . 4 . Only one eye study patient may recruit study . If nonstudy eye treat intravitreal antiVEGF therapy , develop wet AMD , drug use study eye shall use nonstudy eye . Treatment must give doubleblind nonstudy eye well . 1 . Previous treatment CNV study eye . 2 . Participation another AMD study , use investigational medicine . 3 . AntiVEGF treatment nonstudy eye last 4 week . 4 . Earlier current treatment systemic antiVEGF drug . 5 . Subretinal hemorrhage and/or fibrosis involve ≥50 percent CNV lesion study eye . 6 . CNV pathogenesis , pathologic myopia ( defined spherical equivalent &gt; 8 diopter myopia ) Presumed Ocular Histoplasmosis Syndrome ( POHS ) . 7 . Presence retinal disease AMD ( diabetic retinopathy , macular hole , etc ) lead loss visual acuity study eye . 8 . Cataract presumably require operation within 2 year intraocular surgery laser treatment last 3 month . 9 . Impaired visualization retina ( vitreous hemorrhage , corneal dystrophy , etc . ) may hamper adequate diagnosis . 10 . Intraocular pressure ≥25 mm Hg , measure mydriasis , uncontrolled glaucoma evaluate examine ophthalmologist . 11 . Active uveitis study eye intraocular inflammation use Lucentis Avastin nonstudy eye . 12 . Infection one eye . 13 . Premenopausal woman use appropriate birth control , nursing . 14 . Patients mental physical reason unable comply study 's procedure , 15 . Serious disease probability death within duration study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Anti-VEGF</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>exudative</keyword>
	<keyword>macular degeneration</keyword>
</DOC>